The maintenance of health depends on the coordinated and tightly regulated expression of
genetic information. Certain forms of leukemia have become paradigms for the pathogenic …

Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential
anticancer agents for the treatment of solid and hematological malignancies. In recent years …

The antitumor efficacy of the synthetic benzamide derivative MS-27-275 (MS-275), an
inhibitor of histone deacetylation [T. Suzuki et al., J. Med. Chem., 42: 3001–3003, 1999], was …

Acetylation and deacetylation of chromatin histone protein by histone deacetylase (HDAC)
alters chromatin structure and dynamically affects transcriptional regulation. Many lines of …

Histone deacetylase inhibitors (HDACIs) are a new class of chemotherapeutic drugs able to
induce tumor cell apoptosis and/or cell cycle arrest; however, the molecular mechanisms …

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and
genotype-independent manner. Epigenetic modifications mainly encompass CpG island …

We previously reported that apicidin arrested human cancer cell growth through selective
induction of p21 WAF1/Cip1. In this study, the apoptotic potential of apicidin and its …

Histone acetylation has long been associated with transcriptional activation, whereas
conversely, deacetylation of histones is associated with gene silencing and transcriptional …

Histone deacetylase (HDAC) inhibitors are emerging as a promising new treatment strategy
in hematologic malignancies. Here we show that NVP-LAQ824, a novel hydroxamic acid …

A workshop on childhood atypical teratoid/rhabdoid tumors of the central nervous system,
sponsored by the National Cancer Institute and the Pediatric Brain Tumor Foundation of the …